Overall Survival With Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Study Update

home / between-the-lines / overall-survival-with-ciltacabtagene-autoleucel-vs-standard-of-care-in-lenalidomide-refractory

Panelists discuss how the CARTITUDE-4 study data highlights the significant survival benefits of ciltacabtagene autoleucel compared to with standard of care in patients with lenalidomide-refractory multiple myeloma, emphasizing its potential to reshape treatment paradigms in this challenging population.

Impact of CAR T-Cell Therapy in R/R MM

EP. 1: Impact of CAR T-Cell Therapy in R/R MM

Binod Dhakal, MD, MS;Krina K. Patel, MD
October 11th 2024

Panelists discuss how chimeric antigen receptor (CAR) -T-cell therapy has transformed the treatment landscape for relapsed/refractory multiple myeloma (R/R MM), demonstrating remarkable efficacy and offering new hope for patients with limited therapeutic options.